This NIDDK Core Center of Excellence in Hematology (CCEH) provides resources to investigators at the Fred Hutchinson Cancer Research Center (FHCRC) and University of Washington (UW). These resources are designed to overcome obstacles that limit the ability of individual investigators to isolate, functionally characterize, and manipulate hematopoietic stem cells and their progeny. Primary among these limitations is the inability to obtain sufficient quantities of defined cell populations from patients, normal individuals and large animals. This limitation is addressed by the Large-Scale Cell Processing which isolates specific populations of cells from large volumes of human, canine, and non-human primate blood and marrow. This Core also maintains a Repository of cryopreserved specimens from patients with hematologic diseases, and characterizes and maintains a database on all allogeneic transplant components. In addition We are currently developing canine embryonic stem cell lines for the use of CCEH members. the Clonal Analysis provides measures of chimerism in transplant recipients and clonal analysis of gene marked cells using LAM-PCR. We also have molecular biology consultation and tutorials. Vector Production designs and produces retrovirus, lentivirus, and foamy virus vectors for marking and transducing cells. This aids in the tracking of gene-marked cells and provides consultation for experimental design. The NOD/SCID Assay maintains a state-of-the-art in vivo readout of the proliferative and differentiative potential of defined populations of cells. This maintains and provides quality control for breeding stocks of various immunodeficient mice, performs all injections and tissue harvesting, and provides experimental design consultation. Taken together these make it possible for investigators to isolate cells of interest, mark them, alter their function, and accurately detect and quantitate their progeny in vitro and in vivo. These four are supervised and supported by the Administrative one under the direction of CCEH Director Beverly Torok-Storb and Associate Director Shelly Heimfeld. Administrative guidance from external and internal advisors also supports Pilot Studies and an Enrichment Program. There are more than 30 FHCRC-UW based researchers using these esources. Greater than 90%of all grant support comes from the NIH

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
3P30DK056465-11S2
Application #
8034897
Study Section
Special Emphasis Panel (ZDK1-GRB-B (M1))
Program Officer
Bishop, Terry Rogers
Project Start
2010-04-01
Project End
2012-03-31
Budget Start
2010-04-01
Budget End
2012-03-31
Support Year
11
Fiscal Year
2010
Total Cost
$496,515
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
OhAinle, Molly; Helms, Louisa; Vermeire, Jolien et al. (2018) A virus-packageable CRISPR screen identifies host factors mediating interferon inhibition of HIV. Elife 7:
Sorror, Mohamed L; Gooley, Ted A; Maclean, Kirsteen H et al. (2018) Pre-transplant expressions of microRNAs, comorbidities, and post-transplant mortality. Bone Marrow Transplant :
Gauthier, Jordan; Turtle, Cameron J (2018) Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. Curr Res Transl Med 66:50-52
Correnti, Colin E; Laszlo, George S; de van der Schueren, Willem J et al. (2018) Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation. Leukemia 32:1239-1243
Roesch, Ferdinand; OhAinle, Molly; Emerman, Michael (2018) A CRISPR screen for factors regulating SAMHD1 degradation identifies IFITMs as potent inhibitors of lentiviral particle delivery. Retrovirology 15:26
Hay, Kevin A; Turtle, Cameron J (2018) CD19-specific chimeric antigen receptor-modified (CAR)-T cell therapy for the treatment of chronic lymphocytic leukemia in the ibrutinib era. Immunotherapy 10:251-254
Yeung, Cecilia C S; McElhone, Scott; Chen, Xue Yan et al. (2018) Impact of copy neutral loss of heterozygosity and total genome aberrations on survival in myelodysplastic syndrome. Mod Pathol 31:569-580
Gust, Juliane; Hay, Kevin A; Hanafi, Laïla-Aïcha et al. (2017) Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. Cancer Discov 7:1404-1419
Hay, Kevin A; Hanafi, Laïla-Aïcha; Li, Daniel et al. (2017) Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 130:2295-2306
Turtle, Cameron J; Hay, Kevin A; Hanafi, Laïla-Aïcha et al. (2017) Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. J Clin Oncol 35:3010-3020

Showing the most recent 10 out of 267 publications